MX2018013164A - Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. - Google Patents
Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.Info
- Publication number
- MX2018013164A MX2018013164A MX2018013164A MX2018013164A MX2018013164A MX 2018013164 A MX2018013164 A MX 2018013164A MX 2018013164 A MX2018013164 A MX 2018013164A MX 2018013164 A MX2018013164 A MX 2018013164A MX 2018013164 A MX2018013164 A MX 2018013164A
- Authority
- MX
- Mexico
- Prior art keywords
- dioxygenase
- tryptophan
- inhibitors
- indoleamine
- substituted imidazopyridine
- Prior art date
Links
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 title abstract 5
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 title abstract 5
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 title abstract 5
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 title abstract 5
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se divulgan aquí compuestos de imidazopiridina sustituida de fórmula (I) que son inhibidores de las enzimas indolamina-2,3-dioxigenasa (IDO) y/o triptófano-2,3-dioxigenasa (TDO): (ver Fórmula) También se divulgan aquí los usos de los compuestos en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO y/o TDO. También se divulgan aquí composiciones que comprenden estos compuestos. Además, se divulgan aquí los usos de las composiciones en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO y/o TDO.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662329579P | 2016-04-29 | 2016-04-29 | |
| PCT/US2017/029042 WO2017189386A1 (en) | 2016-04-29 | 2017-04-24 | Novel substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013164A true MX2018013164A (es) | 2019-06-24 |
| MX380677B MX380677B (es) | 2025-03-12 |
Family
ID=60161057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013164A MX380677B (es) | 2016-04-29 | 2017-04-24 | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11096930B2 (es) |
| EP (1) | EP3448522B1 (es) |
| JP (1) | JP6948345B2 (es) |
| KR (1) | KR102456521B1 (es) |
| CN (1) | CN109069873B (es) |
| AU (1) | AU2017257377B2 (es) |
| BR (1) | BR112018071602B1 (es) |
| CA (1) | CA3021589A1 (es) |
| MX (1) | MX380677B (es) |
| RU (1) | RU2741911C2 (es) |
| WO (1) | WO2017189386A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019034725A1 (en) | 2017-08-17 | 2019-02-21 | Idorsia Pharmaceuticals Ltd | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND / OR TRYPTOPHAN DIOXYGENASE |
| WO2019138107A1 (en) | 2018-01-15 | 2019-07-18 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3556760A1 (en) * | 2018-04-19 | 2019-10-23 | F. Hoffmann-La Roche AG | Spiro compounds |
| WO2019206800A1 (en) * | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| US20220259212A1 (en) | 2019-07-11 | 2022-08-18 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
| KR102642194B1 (ko) | 2019-10-11 | 2024-03-05 | 삼성전자주식회사 | 전압 컨트롤러 및 이를 포함하는 메모리 장치 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887870B1 (en) * | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| WO2008085302A1 (en) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| EP2118101B1 (en) * | 2007-03-09 | 2012-09-26 | Probiodrug AG | Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase |
| HRP20141094T1 (hr) * | 2008-07-08 | 2015-01-16 | Incyte Corporation | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze |
| EP2817310B1 (en) * | 2012-02-21 | 2018-03-21 | Merck Patent GmbH | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| KR20150126623A (ko) * | 2013-03-14 | 2015-11-12 | 뉴링크 제네틱스 코퍼레이션 | 트립토판 대사로 인한 면역억제의 억제제로서의 삼환식 화합물 |
| JP6313415B2 (ja) * | 2013-03-15 | 2018-04-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｉｄｏ阻害剤 |
| US9931347B2 (en) | 2013-12-03 | 2018-04-03 | Iomet Pharma Ltd. | Pharmaceutical compound |
| AU2015265696B2 (en) * | 2014-05-28 | 2018-01-18 | Astrazeneca Ab | Processes for the preparation of AZD5363 and novel intermediate used therein |
| GB201414730D0 (en) | 2014-08-19 | 2014-10-01 | Tpp Global Dev Ltd | Pharmaceutical compound |
| US20170275302A1 (en) * | 2014-10-14 | 2017-09-28 | Alexander Pasternak | Inhibitors of the renal outer medullary potassium channel |
| MX390081B (es) | 2014-11-03 | 2025-03-20 | Iomet Pharma Ltd | Compuesto farmacéutico. |
| GB201511790D0 (en) * | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
-
2017
- 2017-04-24 CN CN201780026630.8A patent/CN109069873B/zh active Active
- 2017-04-24 EP EP17790165.9A patent/EP3448522B1/en active Active
- 2017-04-24 US US16/088,873 patent/US11096930B2/en active Active
- 2017-04-24 WO PCT/US2017/029042 patent/WO2017189386A1/en not_active Ceased
- 2017-04-24 MX MX2018013164A patent/MX380677B/es unknown
- 2017-04-24 RU RU2018140732A patent/RU2741911C2/ru active
- 2017-04-24 KR KR1020187034045A patent/KR102456521B1/ko active Active
- 2017-04-24 CA CA3021589A patent/CA3021589A1/en active Pending
- 2017-04-24 AU AU2017257377A patent/AU2017257377B2/en not_active Ceased
- 2017-04-24 BR BR112018071602-2A patent/BR112018071602B1/pt active IP Right Grant
- 2017-04-24 JP JP2018555971A patent/JP6948345B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3448522A1 (en) | 2019-03-06 |
| JP6948345B2 (ja) | 2021-10-13 |
| WO2017189386A1 (en) | 2017-11-02 |
| RU2018140732A3 (es) | 2020-06-02 |
| EP3448522A4 (en) | 2019-11-27 |
| CA3021589A1 (en) | 2017-11-02 |
| AU2017257377A1 (en) | 2018-10-11 |
| AU2017257377B2 (en) | 2022-06-23 |
| EP3448522B1 (en) | 2021-01-20 |
| US11096930B2 (en) | 2021-08-24 |
| US20200230117A1 (en) | 2020-07-23 |
| CN109069873B (zh) | 2021-07-20 |
| BR112018071602B1 (pt) | 2024-02-27 |
| RU2018140732A (ru) | 2020-05-29 |
| CN109069873A (zh) | 2018-12-21 |
| MX380677B (es) | 2025-03-12 |
| KR20190003619A (ko) | 2019-01-09 |
| BR112018071602A2 (pt) | 2019-02-12 |
| JP2019515923A (ja) | 2019-06-13 |
| RU2741911C2 (ru) | 2021-01-29 |
| KR102456521B1 (ko) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013164A (es) | Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa. | |
| CY1124061T1 (el) | Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2017001124A1 (es) | Agentes inmunomoduladores | |
| MX2018009645A (es) | Derivados haloalilamina indol y azaindol como inhibidores de lisil-oxidasas y sus usos. | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| EA201790806A1 (ru) | Иммунорегулирующие средства | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| CL2017000992A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasa | |
| MX2016011468A (es) | Inhibidores de calicreína plasmática humana. | |
| PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CO7240375A2 (es) | Compuestos tricíclicos sustituidos como inhibidores del fgfr | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| UY36749A (es) | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| SV2017005381A (es) | Compuestos de imidazopiridazina |